BioPharm International, February 2011 - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

BioPharm International, February 2011
Features
An Economic Comparison of Three Cell Culture Techniques
By Janice Lim , Andrew Sinclair , Jerry Shevitz , John Bonham-Carter
Comparing the economic feasibility of a typical glycosylated protein.
Achieving Process Intensification by Scheduling and Debottlenecking Biotech Processes
By Tarun Sengar , Anurag S. Rathore
An approach to reduce batch time, increase productivity, and decrease costs.
The Quality Product Steward Model: The Genentech Approach
By Jerry Dong , Sharon Ma , Dian Deuerhelm
A successful QPS acts as a single point of contact for consistent product quality oversight.
From the Editor
What a Piece of Work is Pharma
By Michelle Hoffman
Capable of great works, pharma too often yields to the lesser angels of its nature
Regulatory Beat
Congress to Scrutinize FDA Rules, Research Policies
By Jill Wechsler
FDA prepares for top-level changes while promoting transparency and product safety
The Disposables Advisor
Trends Toward Standardization
By Jerold Martin
Although some aspects of single-use components can be standardized, it is unlikely that any materials or design features will become a commodity
Perspectives on Outsourcing
Driving your Product to Profitability with Project Management at the Wheel
By Peter Soelkner
Biotech companies will have a much better shot at success with a project management plan and team in place from the very outset
Final Word
The Powerful Lesson of the GSK–Whistleblower Case
By James W. Matthews , Jason L. Drori
Those at the top must walk the walk of uncompromising commitment to compliance

ADVERTISEMENT

ADVERTISEMENT

Click here